SEC Filing · 6-K
Stevanato Group S.p.A.
STVNNYSEEQUITYCurrent
SEC Filing
Press release in this filing
Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026 →Company context
Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation, and its engineering excellence are central to its ability to offer value added solutions to clients. To learn more, visit: www.stevanatogroup.com.
Current securities
Recent company filings
As-filed source
As filedOpen full document ↗